Matrix Global Advisors
  • Home
  • About
  • News
  • Reports
  • Contact
  • Follow
  • Follow
Taking Stock of the Humira Biosimilars Market

Taking Stock of the Humira Biosimilars Market

Jun 26, 2023 | Commentary

In January, the 21-year monopoly for AbbVie’s blockbuster drug Humira (adalimumab) came to an end with the launch of Amjevita, Amgen’s biosimilar adalimumab.

  • Analysis (49)
  • Books (3)
  • Commentary (15)
  • Events (21)
  • Interviews (59)
  • News (55)
  • Op-Eds (96)
  • Press Releases (4)
  • Testimony (21)
  • a conversation on tax reform
    A Conversation with House Ways and Means Committee Chairman Jason Smith on Tax ReformMarch 5, 2025
  • US Biosimilars Market
    New MGA Paper Identifies Barriers to US Biosimilar Success in the Second DecadeMarch 5, 2025
  • Congress on the Brink of Disrupting the PBM Market
    Congress on the Brink of Disrupting the PBM MarketJanuary 27, 2025
  • Raising the Salt Cap Would Increase Tax Complexity
    Raising the Salt Cap Would Increase Tax ComplexityJanuary 13, 2025
  • Economics of “Delinking” Are Still Not Good
    Economics of “Delinking” Are Still Not GoodDecember 13, 2024
  • Child Tax Credit Tradeoffs
    The Child Tax Credit: Tradeoffs and PreferencesOctober 30, 2024
  • Oregon’s Measure 118 Turnover Tax
    Oregon’s Measure 118: The Turnover Tax Is the WorstOctober 29, 2024
  • Dueling Child Tax Credit Proposals
    Dueling Child Tax Credit Proposals: Harris vs. VanceOctober 21, 2024
  • Deduction for Auto Loan Interest
    Trump Proposes Bringing Back the Deduction for Auto Loan InterestOctober 16, 2024
  • Overtime Income Tax Break
    Overtime Income Tax Break: Not Illogical, Just Costly and ComplicatedOctober 7, 2024
© Copyright 2022 Matrix Global Advisors | Design By DreamBig Creative
MGA
  • Home
  • About
  • News
  • Reports
  • Contact